GILEAD SCIENCES SL

🇪🇸Spain
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
$95.8B
Website
http://www.gilead.com/about/worldwide-operations/europe/spain
Clinical Trials
Related News

COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis

Phase 4
Completed
Conditions
Invasive Aspergillosis
First Posted Date
2006-06-07
Last Posted Date
2015-07-09
Lead Sponsor
Gilead Sciences
Target Recruit Count
30
Registration Number
NCT00334412
Locations
🇫🇷

Gilead Sciences, Paris, France

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Darusentan
Drug: Darusentan Placebo
First Posted Date
2006-05-26
Last Posted Date
2014-03-18
Lead Sponsor
Gilead Sciences
Target Recruit Count
352
Registration Number
NCT00330369
Locations
🇺🇸

CAMC Clinical Trials Center, Charleston, West Virginia, United States

🇺🇸

Innovative Clinical Trials, San Antonio, Texas, United States

🇺🇸

Deerfield Beach Cardiology Associates, Deerfield Beach, Florida, United States

and more 111 locations

PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation

Phase 2
Completed
Conditions
Fungus Diseases
Interventions
Drug: AmBisome
First Posted Date
2006-05-16
Last Posted Date
2010-02-12
Lead Sponsor
Gilead Sciences
Target Recruit Count
34
Registration Number
NCT00326157
Locations
🇮🇹

Gilead Sciences, Milan, Italy

Safety Study of Once a Day ART and Opiate Substitute.

Phase 4
Completed
Conditions
HIV Infections
First Posted Date
2006-05-11
Last Posted Date
2014-03-12
Lead Sponsor
Gilead Sciences
Target Recruit Count
60
Registration Number
NCT00324688
Locations
🇩🇪

Gilead Sciences, Munich, Germany

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

Phase 4
Completed
Conditions
HIV-1
Interventions
Drug: Truvada
Drug: Zidovudine/lamivudine
First Posted Date
2006-05-11
Last Posted Date
2015-08-17
Lead Sponsor
Gilead Sciences
Target Recruit Count
80
Registration Number
NCT00324649
Locations
🇪🇸

Gilead Sciences, S.L., Madrid, Spain

SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada

Phase 4
Completed
Conditions
HIV-1 Infection
First Posted Date
2006-05-09
Last Posted Date
2008-06-09
Lead Sponsor
Gilead Sciences
Target Recruit Count
50
Registration Number
NCT00323687
Locations
🇩🇪

Gilead Sciences GmbH, Martinsried, Germany

TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada

Phase 4
Completed
Conditions
HIV Infections
Interventions
Drug: Truvada
Drug: Current HAART regimen
First Posted Date
2006-05-09
Last Posted Date
2010-01-20
Lead Sponsor
Gilead Sciences
Target Recruit Count
92
Registration Number
NCT00323492
Locations
🇫🇷

Gilead Sciences, Paris, France

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

Phase 3
Completed
Conditions
HIV Infections
First Posted Date
2006-05-09
Last Posted Date
2008-07-04
Lead Sponsor
Gilead Sciences
Target Recruit Count
220
Registration Number
NCT00323544
Locations
🇬🇧

Gilead Sciences, Cambridge, United Kingdom

Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil

First Posted Date
2006-03-28
Last Posted Date
2011-11-01
Lead Sponsor
Gilead Sciences
Target Recruit Count
106
Registration Number
NCT00307489

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

Phase 2
Completed
Conditions
HIV
HIV-1
Human Immunodeficiency Virus
First Posted Date
2006-03-02
Last Posted Date
2008-07-29
Lead Sponsor
Gilead Sciences
Target Recruit Count
278
Registration Number
NCT00298350
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy